GB1570993A - Pharmaceutical tablet formulation - Google Patents
Pharmaceutical tablet formulation Download PDFInfo
- Publication number
- GB1570993A GB1570993A GB20984/76A GB2098476A GB1570993A GB 1570993 A GB1570993 A GB 1570993A GB 20984/76 A GB20984/76 A GB 20984/76A GB 2098476 A GB2098476 A GB 2098476A GB 1570993 A GB1570993 A GB 1570993A
- Authority
- GB
- United Kingdom
- Prior art keywords
- formulation according
- active ingredient
- weight
- tablet
- pyran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000007916 tablet composition Substances 0.000 title claims description 6
- 239000000203 mixture Substances 0.000 claims description 84
- 238000009472 formulation Methods 0.000 claims description 61
- 239000004480 active ingredient Substances 0.000 claims description 33
- 239000000463 material Substances 0.000 claims description 25
- 239000003085 diluting agent Substances 0.000 claims description 20
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 16
- 239000011230 binding agent Substances 0.000 claims description 15
- 239000000314 lubricant Substances 0.000 claims description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 13
- 208000010668 atopic eczema Diseases 0.000 claims description 13
- 206010020751 Hypersensitivity Diseases 0.000 claims description 12
- 230000000172 allergic effect Effects 0.000 claims description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 11
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 11
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 11
- -1 activity Chemical compound 0.000 claims description 10
- 208000030961 allergic reaction Diseases 0.000 claims description 10
- 229960000265 cromoglicic acid Drugs 0.000 claims description 10
- 239000007884 disintegrant Substances 0.000 claims description 9
- 229920000609 methyl cellulose Polymers 0.000 claims description 8
- 239000001923 methylcellulose Substances 0.000 claims description 8
- 235000010981 methylcellulose Nutrition 0.000 claims description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 230000003266 anti-allergic effect Effects 0.000 claims description 5
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- CVQUWLDCFXOXEN-UHFFFAOYSA-N Pyran-4-one Chemical compound O=C1C=COC=C1 CVQUWLDCFXOXEN-UHFFFAOYSA-N 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- 230000002009 allergenic effect Effects 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 3
- 229920003086 cellulose ether Polymers 0.000 claims description 3
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 3
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- RVMGXWBCQGAWBR-UHFFFAOYSA-N 4-oxo-1-benzopyran-2-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)=CC(=O)C2=C1 RVMGXWBCQGAWBR-UHFFFAOYSA-N 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims 5
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 10
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 8
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- MEMWNTAFSYIKSU-UHFFFAOYSA-N pyran Chemical compound O1C=CC=C=C1 MEMWNTAFSYIKSU-UHFFFAOYSA-N 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- 230000036783 anaphylactic response Effects 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920003072 Plasdone™ povidone Polymers 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- DLKZWVIRKURGIR-UHFFFAOYSA-N 4-oxo-10-propyl-6,7,8,9-tetrahydrobenzo[g]chromene-2-carboxylic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1CCCCC1=C2 DLKZWVIRKURGIR-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009924 canning Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002641 lithium Chemical class 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000009725 powder blending Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB20984/76A GB1570993A (en) | 1976-05-21 | 1976-05-21 | Pharmaceutical tablet formulation |
| FR7714858A FR2426460A1 (fr) | 1976-05-21 | 1977-05-16 | Composition antiallergique |
| BE177619A BE854690A (fr) | 1976-05-21 | 1977-05-16 | Composition antiallergique |
| IL52102A IL52102A0 (en) | 1976-05-21 | 1977-05-16 | Novel pharmaceutical formulations comprising anti-allergic drugs and in particular chromone-2-carboxylic acids |
| SE7705850A SE7705850L (sv) | 1976-05-21 | 1977-05-17 | Forfarande for framstellning av en farmaceutisk komposition |
| AU25214/77A AU511269B2 (en) | 1976-05-21 | 1977-05-17 | Anti-allergic tablet compositions |
| NZ184141A NZ184141A (en) | 1976-05-21 | 1977-05-18 | Pharmaceutical tablet formulation containing anti-allergic drug |
| LU77369A LU77369A1 (enrdf_load_stackoverflow) | 1976-05-21 | 1977-05-18 | |
| ZA00772989A ZA772989B (en) | 1976-05-21 | 1977-05-18 | Non-allergenic tablet formulation of anti-allergic drugs |
| DK218777A DK218777A (da) | 1976-05-21 | 1977-05-18 | Fremgangsmade til fremstilling af en farmaceutisk tabletkomposition indeholdende anti-allergisk legemiddel |
| FI771587A FI771587A7 (enrdf_load_stackoverflow) | 1976-05-21 | 1977-05-19 | |
| CA278,833A CA1105835A (en) | 1976-05-21 | 1977-05-19 | Pharmaceutical tablet comprising anti-allergic drug |
| JP5712777A JPS52143220A (en) | 1976-05-21 | 1977-05-19 | Tablet type pharmaceutical composition |
| DE19772722917 DE2722917A1 (de) | 1976-05-21 | 1977-05-20 | Pharmazeutische zusammensetzung |
| IE2005/80A IE45283B1 (en) | 1976-05-21 | 1977-05-20 | Pharmaceutical formulation |
| IE1038/77A IE45282B1 (en) | 1976-05-21 | 1977-05-20 | Pharmaceutical tablet formulation |
| NO771765A NO771765L (no) | 1976-05-21 | 1977-05-20 | Fremgangsm}te til fremstilling av et nytt farmas¦ytisk preparat |
| NL7705560A NL7705560A (nl) | 1976-05-21 | 1977-05-20 | Farmaceutisch preparaat. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB20984/76A GB1570993A (en) | 1976-05-21 | 1976-05-21 | Pharmaceutical tablet formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1570993A true GB1570993A (en) | 1980-07-09 |
Family
ID=10155196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB20984/76A Expired GB1570993A (en) | 1976-05-21 | 1976-05-21 | Pharmaceutical tablet formulation |
Country Status (17)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002087546A3 (en) * | 2001-05-01 | 2003-02-13 | Pfizer Prod Inc | Method for manufacturing a low dose pharmaceutical composition |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1595220A (en) * | 1977-12-23 | 1981-08-12 | Fisons Ltd | Tablets containing 1,3-bis(2-carboxychromon-5-yloxy)-2-hydroxypropane |
| US5447728A (en) * | 1992-06-15 | 1995-09-05 | Emisphere Technologies, Inc. | Desferrioxamine oral delivery system |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA753210B (en) * | 1974-06-14 | 1976-04-28 | Upjohn Co | Novel dosing regimen for intal biologues |
| IL48360A (en) * | 1974-11-09 | 1978-12-17 | Fisons Ltd | Pharmaceutical compositions for the treatment of aphthous stomatitis comprising 1,3-bis-(2-carboxychromon-5-yloxy)-2-carboxychromon-5-yloxy)-2-hydroxypropane |
| CA1065329A (en) * | 1974-11-30 | 1979-10-30 | Richard Hazard | Chromone derivatives |
-
1976
- 1976-05-21 GB GB20984/76A patent/GB1570993A/en not_active Expired
-
1977
- 1977-05-16 FR FR7714858A patent/FR2426460A1/fr active Granted
- 1977-05-16 IL IL52102A patent/IL52102A0/xx unknown
- 1977-05-16 BE BE177619A patent/BE854690A/xx unknown
- 1977-05-17 SE SE7705850A patent/SE7705850L/xx unknown
- 1977-05-17 AU AU25214/77A patent/AU511269B2/en not_active Expired
- 1977-05-18 LU LU77369A patent/LU77369A1/xx unknown
- 1977-05-18 ZA ZA00772989A patent/ZA772989B/xx unknown
- 1977-05-18 NZ NZ184141A patent/NZ184141A/xx unknown
- 1977-05-18 DK DK218777A patent/DK218777A/da not_active Application Discontinuation
- 1977-05-19 JP JP5712777A patent/JPS52143220A/ja active Pending
- 1977-05-19 FI FI771587A patent/FI771587A7/fi not_active Application Discontinuation
- 1977-05-19 CA CA278,833A patent/CA1105835A/en not_active Expired
- 1977-05-20 DE DE19772722917 patent/DE2722917A1/de not_active Ceased
- 1977-05-20 NL NL7705560A patent/NL7705560A/xx not_active Application Discontinuation
- 1977-05-20 IE IE1038/77A patent/IE45282B1/en unknown
- 1977-05-20 NO NO771765A patent/NO771765L/no unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002087546A3 (en) * | 2001-05-01 | 2003-02-13 | Pfizer Prod Inc | Method for manufacturing a low dose pharmaceutical composition |
| US7037530B2 (en) | 2001-05-01 | 2006-05-02 | Pfizer Inc | Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency |
| US7176221B2 (en) | 2001-05-01 | 2007-02-13 | Pfizer Inc. | Low dose pharmaceutical composition having uniform drug distribution and potency |
Also Published As
| Publication number | Publication date |
|---|---|
| LU77369A1 (enrdf_load_stackoverflow) | 1977-12-13 |
| FI771587A7 (enrdf_load_stackoverflow) | 1977-11-22 |
| NZ184141A (en) | 1979-06-19 |
| DE2722917A1 (de) | 1977-12-01 |
| IE45282L (en) | 1977-11-21 |
| IE45282B1 (en) | 1982-07-28 |
| AU511269B2 (en) | 1980-08-07 |
| AU2521477A (en) | 1978-11-23 |
| DK218777A (da) | 1977-11-22 |
| ZA772989B (en) | 1978-04-26 |
| NO771765L (no) | 1977-11-22 |
| JPS52143220A (en) | 1977-11-29 |
| IL52102A0 (en) | 1977-07-31 |
| NL7705560A (nl) | 1977-11-23 |
| FR2426460A1 (fr) | 1979-12-21 |
| SE7705850L (sv) | 1977-11-22 |
| CA1105835A (en) | 1981-07-28 |
| FR2426460B1 (enrdf_load_stackoverflow) | 1983-04-29 |
| BE854690A (fr) | 1977-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3037757B2 (ja) | パロキセチン錠およびその製法 | |
| Murphy et al. | Cromolyn sodium: a review of mechanisms and clinical use in asthma | |
| US3148124A (en) | Method of preparing sustained release pharmaceutical tablets | |
| US4929605A (en) | Pharmaceutical composition for piperidinoalkanol derivatives | |
| CA2447693A1 (en) | Taste-masking of highly water-soluble drugs | |
| EP0324725B1 (en) | A pharmaceutical composition | |
| WO2004019937A1 (en) | Pharmaceutical composition of metaxalone with enhanced oral bioavailability | |
| WO1996031205A1 (en) | Compositions and process for treating uremic pruritus | |
| GB1570993A (en) | Pharmaceutical tablet formulation | |
| AU615950B2 (en) | Pharmaceutical composition for piperidinoalkanol derivatives | |
| US4428951A (en) | Long acting pharmaceutical composition | |
| JPH069391A (ja) | ヒアルロニダーゼ活性阻害剤 | |
| US3224940A (en) | Antacid compositions and method of using same | |
| JPH10218780A (ja) | 肛門直腸疾患および結腸疾患の制御および処置のための新規な薬学組成物およびその製造方法 | |
| CA2216386C (en) | Composition and process for prevention and treatment of cutaneous immediate hypersensitivity reactions | |
| GB2061111A (en) | Long acting pharmaceutical composition | |
| WO1980001242A1 (en) | Galenical preparation | |
| GB1570994A (en) | Pharmaceutical formulation | |
| JPH08325142A (ja) | ヨウ化イソプロパミド含有製剤 | |
| IE45283B1 (en) | Pharmaceutical formulation | |
| US2224256A (en) | Pharmaceutical preparation | |
| NZ207930A (en) | Preparing base salts of piroxicam | |
| US5217965A (en) | Stabilized solid dosage forms of choline metal carboxymethylcellulose salicylate compositions | |
| JPH072697A (ja) | 呼吸性アレルギーに対する局所的製薬組成物 | |
| US3824314A (en) | Anti-inflammatory preparations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| PCNP | Patent ceased through non-payment of renewal fee |